Shares of Aptorum Group Ltd. (APM) jumped over 30% on Wednesday morning after the company received clearance from Canada health regulator to commence a phase 1 trial of ALS-4 for infections caused by staphylococcus aureus.
APM is currently trading at $4.21, up $1.03 or 32.39%, on the Nasdaq.
Aptorum, a biopharmaceutical company focused on infectious diseases, announced that it received clearance from the Public Health Agency of Canada regarding the Clinical Trial Application to commence a Phase 1 study of ALS-4, an orally administered small molecule drug intended to treat infections caused by Staphylococcus aureus including MRSA.
The Phase 1 trial is planned to be conducted in Canada and targeted to recruit up to 48 and 24 healthy volunteers for the single-ascending dose and multiple- ascending dose cohorts, respectively.
The primary objective of the trial is to evaluate the safety and tolerability of of ALS-4 administered orally to healthy subjects.
The secondary objective is to assess the pharmacokinetic profile of ALS-4 administered orally to healthy subjects.
For comments and feedback contact: editorial@rttnews.com
